Clinical trial NCT06857877: Arlington Aging Study
Official title: Arlington Study of Healthy Aging
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Aging
Keywords: Aging
MRI
Cognitive Function
Exercise Science
Remote Monitoring
Lead sponsor: The University of Texas at Arlington
Sponsor class: OTHER
First posted: 2025-03-05
Enrollment: 770
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult men and women currently living in Tarrant County will be contacted through IRB approved flyers, targeted ads (social media), and/or word-of-mouth.

Brief summary: The goal of this observational study is to learn about the mechanisms causing functional decline with age, using exercise science, neuroscience, and remote monitoring.

Specific aims include:

Aim 1: Advance knowledge of the biology of aging and its impact on the prevention, progression, and prognosis of disease and disability.

Aim 2: Determine the effects of personal and societal factors on aging.

Aim 3: Examine the influence of racial/ethnic and sex differences on the biology of aging and its impact on the prevention, progression, and prognosis of disease and disability.

Detailed description: Subjects will be asked to participate in two study visits that may last up to 5 hours each. In some cases, additional visits may be needed to accommodate their schedule, and/or the schedule of the study team. All participants will provide informed consent prior to participating in the study procedures such as demographic, medical history, risk factor assessment; questionnaires; geographic information system analysis; blood pressure measurements; assessment of aerobic exercise capacity, cognitive function; olfactory testing; Dual X-Ray absorbency, fasting followed by venous blood draw, vascular function assessment; testing of muscle strength; short physical performance battery; functional mobility; and remote monitoring. The order of procedures and visits may change depending on participant, staff, equipment, and infrastructure availability/needs. Moreover, procedures may be repeated for data quality purposes, if deemed necessary by the investigators.

Eligibility criteria: Inclusion Criteria:

Phase 1: Young healthy men and women between 18 - 30 years of age, and older men and women between 50 - 80 years of age.

Phase 2: Men and women living in Tarrant County, Texas, between 50 - 80 years of age. In addition, the investigators will study up to 120 younger men and women, between 18-30 years of age, equally divided by race/ethnicity (same as above) and sex, to serve as reference controls.

Exclusion Criteria:

Phase 1: Clinical diagnosis of dementia; major depression (diagnosed by a physician), visual or auditory impairments that preclude neuropsychological testing or otherwise jeopardize the health and wellbeing of the participant during testing, non-ambulatory status (i.e. less than 10 m without mobility aid), shortness of breath while performing normal activities of daily living (walking through grocery store), body mass index \&amp;gt; 45 kg/m2, heart failure or cardiomyopathy, acute coronary syndrome, primary valvular heart disease, severe gait disorder due to musculoskeletal disease or neurological motor deficit (e.g. severe osteoarthritis, lower limb amputation, Parkinson's disease, major stroke with motor sequelae), the use of neuroleptics, participation in a dedicated weight loss program within 6 months before the study; daily consumption of more than two alcoholic beverages; current treatment for cancer, and estimated life expectancy \&amp;lt;4 years. Inclusion/exclusion will be verified using the demographics and medical history.

Phase 2: Clinical diagnosis of dementia; major depression (diagnosed by a physician), visual or auditory impairments that preclude neuropsychological testing or otherwise jeopardize the health and wellbeing of the participant during testing, non-ambulatory status (i.e. less than 10 m without mobility aid), shortness of breath while performing normal activities of daily living (walking through grocery store), body mass index \&amp;gt; 45 kg/m2, heart failure or cardiomyopathy, acute coronary syndrome, primary valvular heart disease, severe gait disorder due to musculoskeletal disease or neurological motor deficit (e.g. severe osteoarthritis, lower limb amputation, Parkinson's disease, major stroke with motor sequelae), the use of neuroleptics, participation in a dedicated weight loss program within 6 months before the study; daily consumption of more than two alcoholic beverages; current treatment for cancer, and estimated life expectancy \&amp;lt;4 years. Inclusion/exclusion will be verified using the demographics and medical history.

Primary outcomes:
measure: Sense of Smell
timeFrame: Baseline
measure: Blood Pressure
timeFrame: Baseline
measure: Street Address
timeFrame: Baseline
measure: Ankle Brachial Index
timeFrame: Baseline
measure: Pulse Wave Velocity
timeFrame: Baseline
measure: Flow- mediated dilation
timeFrame: Baseline
measure: Steps taken
timeFrame: Baseline
measure: Sedentary Time
timeFrame: Baseline
measure: Sleep
timeFrame: Baseline
measure: Medical History Questionnaire
timeFrame: Baseline
measure: Complete blood count
timeFrame: Baseline
measure: Functional Mobility
timeFrame: Baseline
measure: Cognitive Function
timeFrame: Baseline
measure: Lower extremity function
timeFrame: Baseline
measure: Grip strength
timeFrame: Baseline
measure: Bone Density
timeFrame: Baseline
measure: Interstitial glucose
timeFrame: Baseline
measure: Body Composition
timeFrame: Baseline
measure: Ambulatory blood pressure
timeFrame: Baseline
measure: Exercise Capacity
timeFrame: Baseline
measure: Blood lipids
timeFrame: Baseline
measure: Metabolic Panel (blood)
timeFrame: Baseline
measure: Apolipoprotein A
timeFrame: Baseline
measure: Apolipoprotein B
timeFrame: Baseline
measure: Lipoprotein A
timeFrame: Baseline
measure: Blood checmistry panel
timeFrame: Baseline
measure: HbA1C (blood)
timeFrame: Baseline
measure: High sensitivity C reactive protein (blood)
timeFrame: Baseline
measure: Genetic testing
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Arlington
country: United States
facility: University of Texas Arlington
state: Texas
Study officials:
References: